# A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

> **NCT06997029** · PHASE1 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 234 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Advanced Breast Cancer
- Advanced Ovarian Cancer

## Interventions

- **DRUG:** BMS-986500
- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT06997029
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2028-12-14
- **Final completion:** 2028-12-14
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06997029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06997029, "A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06997029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*